Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
The Lancet. Oncology|January 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trialArnaud Scherpereel, Julien Mazieres, Laurent Greillier, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 6, 2012
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancerMaurice Pérol, Christos Chouaid, David Pérol, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
The European Respiratory Journal|February 7, 2015
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokersSébastien Couraud, Pierre-Jean Souquet, Christophe Paris, et al.
Therapeutic Advances in Medical Oncology|June 13, 2022
Paclitaxel-bevacizumab combination in advanced non-squamous non-small-cell lung cancer (NSCLC): AVATAX, a retrospective multicentric studyGeoffroy Bilger, Anne-Claire Toffart, Marie Darrason, et al.
European Journal of Cancer (Oxford, England : 1990)|June 18, 2025
Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDSElisa Gobbini, Alexandra Langlais, Pascale Missy, et al.
Lancet (London, England)|January 1, 2016
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialGérard Zalcman, Julien Mazieres, Jacques Margery, et al.
Lung Cancer (Amsterdam, Netherlands)|June 4, 2015
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world settingMarion Sassier, Audrey Emmanuelle Dugué, Bénédicte Clarisse, et al.
JTO Clinical and Research Reports|September 30, 2021
Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation SubtypesAnne-Marie Ruppert, Michèle Beau-Faller, Didier Debieuvre, et al.
Lung Cancer (Amsterdam, Netherlands)|April 21, 2009
p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestosPascal Andujar, Jinhui Wang, Alexis Descatha, et al.
Pageof 12